These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Erythropoietin: its biological properties and clinical use]. Ermolenko VM; Nikolaev AIu Ter Arkh; 1990; 62(11):141-5. PubMed ID: 2094979 [No Abstract] [Full Text] [Related]
23. Treatment of anaemia of progressive renal failure with recombinant human erythropoietin. A preliminary report. Salim KA; Salim S; Mathew T J Assoc Physicians India; 1992 Jan; 40(1):42-3. PubMed ID: 1634463 [TBL] [Abstract][Full Text] [Related]
24. Nutritional implications of recombinant human erythropoietin therapy in renal disease. Sanders HN; Rabb HA; Bittle P; Ramirez G J Am Diet Assoc; 1994 Sep; 94(9):1023-9. PubMed ID: 8071484 [TBL] [Abstract][Full Text] [Related]
25. The management of anemia in pediatric peritoneal dialysis patients. Guidelines by an ad hoc European committee. Schröder CH; Pediatr Nephrol; 2003 Aug; 18(8):805-9. PubMed ID: 12750985 [TBL] [Abstract][Full Text] [Related]
26. Back to the basics in iron management for the patient receiving epoetin therapy. Kirlin L ANNA J; 1991 Aug; 18(4):428. PubMed ID: 1872645 [No Abstract] [Full Text] [Related]
27. Treatment of the anaemia of chronic renal failure with recombinant human erythropoietin. Winearls CG Drugs; 1989 Sep; 38(3):342-5. PubMed ID: 2806134 [No Abstract] [Full Text] [Related]
29. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178 [TBL] [Abstract][Full Text] [Related]
30. [Review of the scientific evidence of the efficiency of erythropoietin use]. García-Altés A; Puig-Junoy J Med Clin (Barc); 2006 Sep; 127(11):415-20. PubMed ID: 17020686 [No Abstract] [Full Text] [Related]
31. Considerations for optimal iron use for anemia due to chronic kidney disease. Hudson JQ; Comstock TJ Clin Ther; 2001 Oct; 23(10):1637-71. PubMed ID: 11726002 [TBL] [Abstract][Full Text] [Related]
32. Effects of azathioprine on response of renal anaemia to subcutaneous recombinant human erythropoietin. Howarth JE; Waters HM; Shanks D; Hyde K; Yin JA; Geary CG; Anastassiades E; Howarth D; Gokal R J Clin Pathol; 1993 Jan; 46(1):41-4. PubMed ID: 8432886 [TBL] [Abstract][Full Text] [Related]
34. A pegylated epoetin in anaemia of renal disease: non-inferiority for an unvalidated surrogate. Walker RG; Strippoli GF Lancet; 2007 Oct; 370(9596):1395-6. PubMed ID: 17950848 [No Abstract] [Full Text] [Related]
35. Erythropoietin: from mountain top to bedside. Erslev AJ; Caro J Adv Exp Med Biol; 1989; 271():1-7. PubMed ID: 2486278 [No Abstract] [Full Text] [Related]
36. [Current issues in erythropoietin therapy of renal anemia]. Zakar G Lege Artis Med; 2007 Oct; 17(10):667-73. PubMed ID: 19227596 [TBL] [Abstract][Full Text] [Related]
37. Treatment of the anaemia of end-stage renal disease with recombinant human erythropoietin. Verbeelen D; Hauglustaine D; Sennesael J Neth J Med; 1988 Aug; 33(1-2):60-7. PubMed ID: 3247012 [No Abstract] [Full Text] [Related]